Whatever did happen to the focus upon breast cancer and why has blood borne cancers become the compelling target. If I was to have a stab at an answer then I would think its most likely contained on slide 20 in relation to Essential Requirements for Preclinical Deals.
According to the AGM presentation, work on developing a clear and compelling commercial target product profile is now marked ongoing. That appears to be an advance compared to the investor presentation back in April 2015. The reasons are unclear but it appears that - in engaging with key clinical experts - blood cancers represent a more compelling commercial target than breast cancers. That's not to say that breast cancer does not represent a future target but that the externally facilitated process recommends going with blood cancers.
I suspect (and hope) that the process is driven by pharmaceutical interest in Phylogica's oncology program. It appears to be a case of working on the edge where doable and understandable collide.
PYC Price at posting:
1.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)